CYTH
Cyclo Therapeutics, Inc. Common StockCYTH
CYTH
Delisted
CYTH was delisted on the 25th of March, 2025.
About: Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Employees: 8
Financial journalist opinion
Neutral
Business Wire
3 months ago
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeutics, Inc. (the “Company”) (NasdaqCM: CYTH) and Rafael Holdings, Inc. (NYSE: RFL). KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company's shareholders. If you would like to discuss your legal rights regarding th.
Neutral
Business Wire
3 months ago
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and challenging diseases, today announced the presentation of data from its ongoing Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) at the 21st Annual WOR.
Neutral
Business Wire
4 months ago
Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstracts have been accepted for oral and poster presentation at the 21st Annual WORLDSymposium™ being held February 3-7, 2025 in San Diego, CA. Details of the presentations are as follows: Oral P.
Neutral
PRNewsWire
5 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders
NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Liberty TripAdvisor Holdings, Inc. (OTCMKTS: LTRPA, LTRPB)'s sale to Tripadvisor, Inc. If you are a Liberty TripAdvisor shareholder, click here to learn more about your legal rights and options . Cyclo Therapeutics, Inc. (NASDAQ: CYTH)'s merger with Rafael Holdings, Inc. If you are a Cyclo shareholder, click here to learn more about your rights and options.
Neutral
GlobeNewsWire
6 months ago
Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Niemann-Pick disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Niemann-Pick disease - Pipeline Insight, 2024," report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Niemann-Pick disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Negative
Zacks Investment Research
6 months ago
Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.29 per share a year ago.
Neutral
Business Wire
6 months ago
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2024 and provided a business update. “The third quarter has been marked by important advancements on our clinical and corporate fronts. We are poised to comp.
Neutral
Business Wire
8 months ago
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the presentation of positive preliminary data from its ongoing pivotal Phase 3 study (“TransportNPC™”) and substudy evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1).
Neutral
Business Wire
9 months ago
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeutics, Inc. (the “Company”) (NasdaqCM: CYTH) and Rafael Holdings, Inc. (NYSE: RFL). KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company's shareholders. If you would like to discuss your legal rights regarding th.
Neutral
PRNewsWire
9 months ago
Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings. Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
Charts implemented using Lightweight Charts™